UPADACITINIB

Brand name:

• Rinvoq®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Abbvie Pty Ltd

Condition/indication:
(therapeutic use)

• Severe atopic dermatitis

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Category 2)

Comment:

Item was considered by PBAC between its July 2021 and November 2021 meeting.

Other PBAC consideration:

• UPADACITINIB

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

05/10/2021

Lodgement of required documentation:

15/10/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 01/11/2021

Status:

Finalised

Government processes:

Commenced on 23/11/2021

Medicine listed on the PBS:

01/02/2022 (see PBS schedule)